1. Home
  2. WKSP vs INAB Comparison

WKSP vs INAB Comparison

Compare WKSP & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Worksport Ltd.

WKSP

Worksport Ltd.

HOLD

Current Price

$0.68

Market Cap

13.2M

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$0.96

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WKSP
INAB
Founded
2003
2016
Country
United States
United States
Employees
81
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
13.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
WKSP
INAB
Price
$0.68
$0.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$9.25
$6.00
AVG Volume (30 Days)
340.5K
53.6K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$131.96
N/A
Revenue Next Year
$24.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.96
52 Week High
$4.30
$2.73

Technical Indicators

Market Signals
Indicator
WKSP
INAB
Relative Strength Index (RSI) 46.91 24.32
Support Level $0.59 N/A
Resistance Level $1.03 $1.50
Average True Range (ATR) 0.07 0.06
MACD -0.00 -0.02
Stochastic Oscillator 47.17 13.86

Price Performance

Historical Comparison
WKSP
INAB

About WKSP Worksport Ltd.

Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: